Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Diluted Average) (2020 - 2024)

Historic Shares Outstanding (Diluted Average) for KalVista Pharmaceuticals (KALV) over the last 3 years, with Q4 2024 value amounting to $46.7 million.

  • KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) rose 3509.02% to $46.7 million in Q4 2024 from the same period last year, while for Oct 2024 it was $46.7 million, marking a year-over-year increase of 3509.02%. This contributed to the annual value of $36.8 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $46.7 million, which was up 3509.02% from $46.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $46.7 million for Q4 2024, and its period low was $17.7 million during Q2 2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $35.9 million, with a median of $34.7 million in 2024.
  • Examining YoY changes over the last 5 years, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) showed a top increase of 3509.02% in 2024 and a maximum decrease of 3434.26% in 2024.
  • Over the past 3 years, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $17.7 million in 2020, then surged by 94.75% to $34.6 million in 2023, then surged by 35.09% to $46.7 million in 2024.
  • Its Shares Outstanding (Diluted Average) stands at $46.7 million for Q4 2024, versus $46.2 million for Q3 2024 and $36.8 million for Q2 2024.